Innovation and efficiency for a more sustainable future in the pharmaceutical industry

The pharmaceutical industry is one of the most essential industries in our society, and its contribution to the health of millions of people worldwide is unquestionable. Due to its characteristics, to guarantee the safety and quality of medicines, the sector needs to operate with the highest standards of control in air conditioning, ventilation, lighting, and production processes. All of this necessarily implies high energy consumption, which opens the door to significant opportunities for improvement through efficiency and sustainability. Furthermore, in recent years, energy efficiency and decarbonization have gone further and have become more than just a sustainability issue; they have become a key factor in strengthening the competitiveness of this sector. At Edison Next, we have been accompanying different pharmaceutical companies along this path for years, helping them optimize consumption, incorporate renewable energies, and digitize their facilities to improve performance and reduce their environmental impact. Among the solutions that, based on our experience, are providing the most value today is the implementation of Building Management System (BMS) systems, which allow us to control, monitor, and optimize air conditioning, ventilation, lighting, and auxiliary processes in real time. In a sector like this, where the stability of environmental conditions is critical, this solution guarantees us efficiency and reliability, in addition to anticipating potential incidents. Another fundamental axis of our proposal is the decarbonization of thermal energy. Technologies such as industrial heat pumps, mechanical vapor compression, electric or hybrid boilers, and heat recovery systems are enabling our clients to reduce emissions linked to heat generation. Adapted to the characteristics of each plant, these solutions offer measurable savings and, if combined with mechanisms such as Energy Savings Certificates (CAEs), they become an investment that maximizes economic return. Through our role as Delegated Entity at Edison Next, we not only execute and launch these projects, but also certify and monetize the savings, so that our clients recover part of the investment allocated to these projects and reinforce the viability of their sustainability plans. With more than 2,500 projects developed for industrial clients, including leaders in the pharmaceutical sector, we have demonstrated that moving towards a more sustainable model is possible without sacrificing quality or safety. We will continue working hand in hand with the pharmaceutical industry so that its role in health also translates into a solid commitment to the future of the planet.